Learn languages naturally with fresh, real content!
Popular Topics
Explore By Region
Ocular Therapeutix announces positive Phase 2 PAXTRAVA™ glaucoma data, showing sustained IOP reductions with a single implant for six months.
Ocular Therapeutix announces positive Phase 2 PAXTRAVA™ glaucoma data, showing consistent and sustained IOP reductions (p<0 .0001) < a for implant. months single six span with> Results indicate 24-30% reductions and good tolerance with no corneal health impact. The study suggests potential for repeat dosing without implant stacking, and the company plans to expand its focus on retinal diseases. 5 Articles